Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Rene Bruno"'
Autor:
Anita Moein, Tong Lu, Siv Jönsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina Tang, Young S. Oh, Rene Bruno, Rui Zhu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 9, Pp 1244-1255 (2022)
Abstract Etrolizumab is an IgG1‐humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately‐to‐severely active ulcerative colitis (UC). Popul
Externí odkaz:
https://doaj.org/article/7c12ab9b159c4fe5999ad5c1bde26078
Autor:
Benjamin Wu, Nitzan Sternheim, Priya Agarwal, Julia Suchomel, Shweta Vadhavkar, Rene Bruno, Marcus Ballinger, Coen A. Bernaards, Phyllis Chan, Jane Ruppel, Jin Jin, Sandhya Girish, Amita Joshi, Valerie Quarmby
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 1, Pp 130-140 (2022)
Abstract Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA)
Externí odkaz:
https://doaj.org/article/5e1e06bc19ff493482ec25b2f5e80c9f
Autor:
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, Sandhya Girish
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposu
Externí odkaz:
https://doaj.org/article/b996c2b9893a413b9905987d3a8dc5c2
Autor:
Alyse Lin, Benjamin Wu, Phyllis Chan, Jin Y. Jin, Mathilde Marchand, Rene Bruno, Kenta Yoshida, Shweta Vadhavkar, Nitzan Sternheim, Marcus Ballinger, Nina Wang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1171-1182 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth inhibition (TGI) metrics and assess the impact of TGI metrics and baseline prognostic factors on
Autor:
Benjamin Wu, Mathilde Marchand, Nitzan Sternheim, Rene Bruno, Valerie Quarmby, Marcus Ballinger, Rong Zhang, Jin Y. Jin, Phyllis Chan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:211-221
The time-varying clearance (CL) of the PD-L1 inhibitor atezolizumab was assessed on a population of 1519 cancer patients (primarily with non-small-cell lung cancer or metastatic urothelial carcinoma) from three clinical studies. The first step was to
Autor:
Luna Musib, Josina C. Reddy, Sravanthi Cheeti, Sandhya Girish, Jin Y. Jin, Pascal Chanu, Rene Bruno, Tong Lu, Ivor Caro, Xin Wang
Publikováno v:
Journal of Investigative Dermatology. 141:930-933
Summary Long-term use of vismodegib is associated with treatment-emergent adverse drug reactions in clinical trials of patients with locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC). Treatment interruptions have been recommende
Autor:
Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y. Jin, Jérémie Guedj, René Bruno
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 1017-1028 (2024)
Abstract Model‐based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding the differences between two
Externí odkaz:
https://doaj.org/article/edf64a1ef2e3434b96731dc8aefa04d5
Autor:
Russ Wada, Kris M. Jamsen, Sandhya Girish, Colby S. Shemesh, Helen Winter, Xin Wang, Jane Ruppel, Gianluca Rossato, Rene Bruno, Pascal Chanu, Francis Donaldson, Amit Garg, Jin Jin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety
Autor:
Solange Peters, Alexandr Vilimovskij, Nitzan Sternheim, Marcus Ballinger, Valerie Quarmby, Jane Ruppel, Benjamin Wu, Rene Bruno, Peter R. Galle, Coen Bernaards, Martin Reck
Publikováno v:
Clinical and Translational Science
Clinical and translational science, vol. 15, no. 1, pp. 141-157
Clinical and Translational Science, Vol 15, Iss 1, Pp 141-157 (2022)
Clinical and translational science, vol. 15, no. 1, pp. 141-157
Clinical and Translational Science, Vol 15, Iss 1, Pp 141-157 (2022)
Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. I
Autor:
Rene Bruno, Nitzan Sternheim, Valerie Quarmby, Marcus Ballinger, Jin Jin, Phyllis Chan, Benjamin Wu, Jane Ruppel, Amita Joshi, Priya Agarwal, Sandhya Girish, Coen Bernaards, Shweta Vadhavkar, Julia Suchomel
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 15, Iss 1, Pp 130-140 (2022)
Clinical and Translational Science, Vol 15, Iss 1, Pp 130-140 (2022)
Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA) on the P